id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-1079-0005,FDA,FDA-2019-E-1079,Determination of Regulatory Review Period for Purposes of Patent Extension: PALYNZIQ,Notice,Determinations,2019-12-06T05:00:00Z,2019,12,2019-12-06T05:00:00Z,2020-06-04T03:59:59Z,2019-12-06T14:26:16Z,2019-26327,0,0,09000064841ed900
FDA-2019-E-1079-0004,FDA,FDA-2019-E-1079,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T19:29:19Z,,0,0,090000648411646c
FDA-2019-E-1079-0003,FDA,FDA-2019-E-1079,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T19:08:28Z,,0,0,0900006483c73e64
FDA-2019-E-1079-0002,FDA,FDA-2019-E-1079,"Patent Extension Application for PALYNZIQ Patent No. 7,537,923",Other,Application,2019-03-06T05:00:00Z,2019,3,2019-03-06T05:00:00Z,,2019-03-06T17:57:13Z,,0,0,0900006483ac4cb9
FDA-2019-E-1079-0001,FDA,FDA-2019-E-1079,Letter from U S Patent and Trademark Office,Other,Letter(s),2019-03-06T05:00:00Z,2019,3,2019-03-06T05:00:00Z,,2019-03-06T17:55:54Z,,0,0,0900006483ac4cb7